Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for Endari™ (L-glutamine oral powder)
Emmaus Life Sciences, Inc., announces it has entered into a distribution agreement with McKesson Plasma and Biologics LLC (McKesson), a division of McKesson Corporation. The agreement makes Endari™ (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, available nationwide to pharmacies that utilize McKesson as their primary and exclusive distributor. McKesson is the largest healthcare distribution company in the world.
Since launching Endari, the first U.S. FDA approved sickle cell treatment in 20 years, Emmaus has brought this therapy to patients in over 30 states, Washington DC and Puerto Rico. In addition to the distributors already in place, this agreement with McKesson will further broaden Endari’s distribution, with the potential to reach many more patients suffering from the acute complications associated with sickle cell disease.
“As the demand for Endari continues to increase, we seek to build our distribution network to ensure that we reach patients in need,” said Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus.
+myBinderRelated Content
-
L-Glutamine for sickle cell anemia: More questions than answersIn 2017, the Food and Drug Administratio...
-
Phase 3 Study of L-Glutamine Therapy in Sickle Cell Anemia and Sickle ß0-Thalassemia Subgroup Analyses Show Consist...Background: Sickle cell disease (SCD) is...
-
FDA Approves Glutamine Powder for Sickle Cell DiseaseThe U.S. Food and Drug Administration ap...
-
Advances in the Treatment of Sickle Cell Disease: L-Glutamine, Crizanlizumab & Gene Therapyhttps://www.youtube.com/watch?v=wkm4axJ3...
-
Sickle Cell Treatment Endari Now Available in the United StatesEmmaus Life Sciences has announced that ...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.